

CURRENT REPORT 4/2024

January 30, 2024

Registration of series K subscription warrants of the Company with the National Depository for Securities

The Management Board of Ryvu Therapeutics S.A. with its registered office in Krakow (the „Company”), with reference to current report no. 14/2022 of 17 August 2022, no. 19/2023 of 5 May 2023, no. 33/2023 of 19 June 2023 and no. 2/2024 of 18 January 2024, hereby informs that on January 30, 2024, the National Depository for Securities (in Polish: Krajowy Depozyt Papierów Wartościowych S.A.) issued a statement on registration on February 1, 2024 in the securities depository of 592,825 (five hundred and ninety-two thousand eight hundred and twenty-five) series K subscription warrants under ISIN code PLSELVT00088.

Disclaimer: This English language translation has been prepared solely for the convenience of English-speaking readers. Despite all the efforts devoted to this translation, certain discrepancies, omissions or approximations may exist. In case of any differences between the Polish and the English versions, the Polish version shall prevail. Ryvu Therapeutics S.A., its representatives and employees decline all responsibility in this regard.

Legal basis: Art. 17 (1) MAR - inside information

Representatives of the Issuer:

- Paweł Przewięźlikowski – President of the Management Board
- Kamil Sitarz – Member of the Management Board